Targeting the p53 signaling pathway in cancers: Molecular mechanisms and clinical studies
The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Tumor suppressor p53 can transcriptionally activate downstream genes in response to stress, and then regulate the cell cycle, DNA repair, metabolism, angiogenesis, apoptosis, and other biological responses. p53 has seven functional domains and 12 splice isoforms, and different domains and subtypes play different roles. The activation and inactivation of p53 are finely regulated and are associated with phosphorylation/acetylation modification and ubiquitination modification, respectively. Abnormal activation of p53 is closely related to the occurrence and development of cancer. While targeted therapy of the p53 signaling pathway is still in its early stages and only a few drugs or treatments have entered clinical trials, the development of new drugs and ongoing clinical trials are expected to lead to the widespread use of p53 signaling‐targeted therapy in cancer treatment in the future. TRIAP1 is a novel p53 downstream inhibitor of apoptosis. TRIAP1 is the homolog of yeast mitochondrial intermembrane protein MDM35, which can play a tumor‐promoting role by blocking the mitochondria‐dependent apoptosis pathway. This work provides a systematic overview of recent basic research and clinical progress in the p53 signaling pathway and proposes that TRIAP1 is an important therapeutic target downstream of p53 signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inferring tumour purity and stromal and immune cell admixture from expression data
Yoshihara, K., Shahmoradgoli, M., Martínez, E., Vegesna, R., Kim, H., Torres-Garcia, W., Treviño, V., Shen, H., Laird, P. W., Levine, D. A., et al. (2013) · Nature Communications · doi:10.1038/ncomms3612 · Cited by 9,778
mTOR: from growth signal integration to cancer, diabetes and ageing
Zoncu, R., Efeyan, A., & Sabatini, D. M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3025 · Cited by 3,941
p21 in cancer: Intricate networks and multiple activities
Abbas, T., & Dutta, A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2657 · Cited by 2,712
Mitochondria and cell death: outer membrane permeabilization and beyond
Tait, S. W. G., & Green, D. R. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2952 · Cited by 2,593
Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation
Malta, T. M., Sokolov, A., Gentles, A. J., Burzykowski, T., Poisson, L., Weinstein, J. N., Kamińska, B., Huelsken, J., Omberg, L., Gevaert, O., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.034 · Cited by 2,180
Role of hypoxia in cancer therapy by regulating the tumor microenvironment
Jing, X., Yang, F., Shao, C., Wei, K., Xie, M., Shen, H., & Shu, Y. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1089-9 · Cited by 2,054
TIGAR, a p53-Inducible Regulator of Glycolysis and Apoptosis
Bensaad, K., Tsuruta, A., Selak, M. A., Vidal, M. N. C., Nakano, K., Bartrons, R., Gottlieb, E., & Vousden, K. H. (2006) · Cell · doi:10.1016/j.cell.2006.05.036 · Cited by 2,019
The functions and regulation of the PTEN tumour suppressor
Song, M. S., Salmena, L., & Pandolfi, P. P. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3330 · Cited by 1,926
Kastenhuber, E. R., & Lowe, S. W. (2017) · Cell · doi:10.1016/j.cell.2017.08.028 · Cited by 1,906
AMP-activated protein kinase induces a p53-dependent metabolic checkpoint
Jones, R. G., Plas, D. R., Kubek, S., Buzzai, M., Mu, J., Xu, Y., Birnbaum, M. J., & Thompson, C. B. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.03.027 · Cited by 1,619
Research works printed but not linked: 376
- 10.3390/cancers14235733 · DOI
- 10.1016/0016-5085(94)90431-6 · DOI
- 10.1016/j.tcb.2009.10.002 · DOI · Paper page
- 10.1016/j.tibs.2015.04.007 · DOI
- 10.1016/j.tig.2022.02.010 · DOI · Paper page
- 10.1038/nrc1954 · DOI · Paper page
- 10.1007/s00018-022-04505-w · DOI
- 10.4161/cc.4.9.1981 · DOI · Paper page
- 10.3389/fcell.2022.818744 · DOI
- 10.1038/sj.emboj.7600608 · DOI · Paper page
- 10.1200/JCO.2005.05.019 · DOI · Paper page
- 10.1016/j.celrep.2019.07.001 · DOI · Paper page
- 10.3389/fonc.2022.1006959 · DOI
- 10.1016/j.cell.2022.10.004 · DOI · Paper page
- 10.1080/15548627.2021.2008752 · DOI
- 10.1016/j.molcel.2021.08.023 · DOI
- 10.1021/jacs.1c06169 · DOI
- 10.1186/s13045-021-01169-0 · DOI · Paper page
- 10.1186/s40164-022-00317-7 · DOI · Paper page
- 10.1016/j.lfs.2022.121361 · DOI
- 10.1038/s41467-023-36755-y · DOI
- 10.1002/hep.30807 · DOI
- 10.1200/JCO.2002.20.4.883 · DOI
- 10.1016/j.cbpa.2022.102230 · DOI
- 10.3390/ijms232113287 · DOI
- 10.3389/fonc.2022.1000677 · DOI
- 10.1158/2159-8290.CD-22-1131 · DOI
- 10.1126/scitranslmed.aay2163 · DOI
- 10.1097/JTO.0000000000000584 · DOI
- 10.1093/jnci/djp376 · DOI
- 10.1093/jmcb/mjaa040 · DOI · Paper page
- 10.1038/s41573-022-00571-8 · DOI · Paper page
- Li W, 2022, Early biomarkers associated with P53 signaling for acute radiation injury, Life (Basel), 12
- 10.3389/fgene.2022.855355 · doi:10.3389/fgene.2022.855355
- 10.1159/000501633 · DOI
- 10.1371/journal.pgen.1000129 · DOI · Paper page
- 10.1158/2159-8290.CD-22-0332 · DOI · Paper page
- 10.3390/ijms21010013 · DOI
- 10.3390/biom12111558 · DOI
- 10.2174/138920107783018444 · DOI · Paper page
- 10.1038/sj.cdd.4401914 · DOI · Paper page
- 10.1038/s41419-022-05349-9 · DOI
- 10.1038/onc.2010.266 · DOI
- 10.4161/cc.8.8.8251 · DOI · Paper page
- 10.1126/sciadv.abi6684 · DOI
- 10.3390/cancers12113422 · DOI
- 10.1016/j.febslet.2010.10.005 · DOI · Paper page
- 10.1038/cdd.2014.73 · DOI
- 10.1038/ncomms5706 · DOI
- 10.1038/s41375-022-01634-w · DOI · Paper page
- 10.1038/s41467-021-20928-8 · DOI
- 10.1021/acs.accounts.7b00473 · DOI
- 10.1016/j.molcel.2019.03.032 · DOI
- 10.3390/cancers11081079 · DOI
- 10.21037/atm.2020.02.142 · DOI
- 10.1016/j.drup.2019.100671 · DOI · Paper page
- 10.1161/CIRCULATIONAHA.113.005224 · DOI
- 10.1093/nar/gkab222 · DOI
- 10.1038/s41556-020-0559-z · DOI · Paper page
- 10.1101/cshperspect.a000950 · DOI · Paper page
- 10.1101/cshperspect.a026047 · DOI · Paper page
- 10.1038/s41417-022-00513-x · DOI
- 10.1182/blood.2020009997 · DOI
- 10.1016/j.molcel.2020.07.021 · DOI
- 10.1016/j.ccr.2006.10.012 · DOI
- 10.1186/1476-4598-12-35 · DOI
- 10.1038/s41467-022-35089-5 · DOI
- 10.1126/scisignal.aao4170 · DOI · Paper page
- 10.1038/onc.2009.71 · DOI · Paper page
- 10.1016/S0092-8674(00)00073-8 · DOI · Paper page
- 10.1038/onc.2010.115 · DOI
- 10.1186/s13046-022-02288-3 · DOI
- 10.18632/oncotarget.9046 · doi:10.18632/oncotarget.9046
- 10.1136/gutjnl-2020-321386 · DOI
- 10.1038/s41417-020-0175-x · DOI
- 10.7150/thno.21963 · DOI
- 10.1158/0008-5472.CAN-20-1804 · DOI
- 10.1074/jbc.M210696200 · DOI · Paper page
- Scolnick DM, 1997, CREB‐binding protein and p300/CBP‐associated factor are transcriptional coactivators of the p53 tumor suppressor protein, Cancer Res, 57, 3693
- 10.1158/1078-0432.CCR-05-1230 · DOI
- 10.1016/j.arr.2018.02.004 · DOI · Paper page
- 10.1016/j.canlet.2015.04.015 · DOI
- 10.1016/S0092-8674(00)80521-8 · DOI · Paper page
- 10.1016/j.celrep.2016.09.022 · DOI · Paper page
- 10.1016/j.bbrc.2014.08.122 · DOI
- 10.1371/journal.pone.0115401 · DOI · Paper page
- 10.1158/0008-5472.CAN-18-2357 · DOI
- 10.3390/ijms222413198 · DOI
- 10.1007/2789_2008_105 · DOI
- 10.1038/nature02514 · DOI · Paper page
- 10.1038/nsmb.1521 · DOI · Paper page
- 10.1038/emboj.2011.125 · DOI
- 10.1016/j.omtm.2021.01.015 · DOI
- 10.1016/j.bbrc.2007.11.176 · doi:10.1016/j.bbrc.2007.11.176
- 10.1021/acs.chemrev.6b00737 · DOI · Paper page
- 10.1593/neo.06439 · DOI
- 10.1007/s12026-022-09334-4 · doi:10.1007/s12026-022-09334-4
- 10.1038/s41467-019-09471-9 · DOI
- 10.1016/j.molcel.2006.05.016 · DOI · Paper page
- 10.3390/cancers14112806 · DOI
- 10.1002/anie.202215704 · DOI
- 10.1002/advs.202206169 · DOI
- 10.1016/S1470-2045(22)00633-7 · DOI
- 10.4161/cc.21235 · DOI
- 10.1093/nar/gkt012 · DOI · Paper page
- 10.1016/j.cell.2007.03.048 · DOI · Paper page
- 10.3390/ijms23158187 · DOI
- 10.1016/j.tig.2020.12.005 · DOI · Paper page
- 10.1016/j.arr.2009.04.005 · DOI
- 10.1016/j.drup.2022.100805 · DOI
- 10.1146/annurev-biochem-052521-035949 · DOI
- 10.7150/jca.81027 · DOI
- 10.1371/journal.pgen.1010012 · DOI
- 10.1093/narcan/zcab026 · DOI
- 10.1038/s41418-022-00962-9 · DOI
- 10.1038/s41589-023-01267-9 · DOI
- 10.1038/s41586-019-1678-1 · DOI · Paper page
- 10.1038/s41467-018-05567-w · DOI · Paper page
- 10.15252/embj.201797833 · DOI
- 10.1016/j.ijbiomac.2023.123180 · DOI
- 10.1016/j.cbpa.2022.102259 · DOI
- 10.1016/j.bbrc.2019.06.152 · DOI
- 10.1016/j.bbrc.2021.01.074 · DOI
- 10.7150/ijbs.69784 · DOI
- 10.1038/leu.2016.293 · DOI
- 10.1007/s11033-010-0099-x · DOI
- 10.1038/s41598-017-17973-z · DOI
- 10.1158/0008-5472.CAN-14-2430 · DOI
- 10.1016/S0378-1119(01)00543-1 · DOI
- 10.1128/MCB.00821-08 · DOI
- 10.1016/j.tig.2021.03.001 · DOI
- 10.1016/j.tig.2020.01.001 · DOI
- 10.3390/cancers13143415 · DOI
- 10.1016/j.yexcr.2006.01.020 · DOI
- 10.1128/MMBR.64.2.435-459.2000 · DOI · Paper page
- 10.1080/15548627.2022.2062112 · DOI · Paper page
- 10.1016/j.ejmech.2022.115020 · DOI
- 10.1182/blood.2019003439 · DOI
- 10.1016/j.semcdb.2022.04.001 · DOI
- 10.1016/j.molmed.2013.07.005 · DOI · Paper page
- 10.1146/annurev-biochem-082411-113907 · DOI · Paper page
- 10.3390/cells7050036 · DOI
- 10.3892/ijo.2014.2377 · DOI
- 10.1016/S0968-0004(02)02166-7 · DOI · Paper page
- 10.1016/j.febslet.2010.09.019 · DOI
- 10.26508/lsa.202201472 · DOI
- 10.18632/oncotarget.2081 · DOI
- 10.1007/s00280-019-03923-1 · DOI
- 10.1016/j.febslet.2010.06.027 · DOI
- 10.1002/hep.24329 · DOI
- 10.1038/sj.emboj.7600836 · DOI
- 10.1016/j.molcel.2013.05.006 · DOI
- 10.1038/onc.2009.314 · DOI
- 10.1038/cdd.2010.168 · DOI
- 10.1161/01.RES.0000253975.76198.ff · DOI · Paper page
- 10.1161/CIRCULATIONAHA.113.002434 · DOI · Paper page
- 10.1182/blood-2005-08-3273 · DOI · Paper page
- 10.1016/j.phrs.2023.106696 · DOI
- 10.1021/acs.jmedchem.1c00940 · DOI · Paper page
- 10.1007/s12032-022-01929-z · DOI
- 10.1073/pnas.0908027106 · DOI · Paper page
- 10.1093/hmg/ddh165 · DOI
- 10.1186/1471-2121-3-30 · DOI
- 10.1016/j.jep.2022.116046 · DOI
- Jiang W, 2020, Hsa‐miR‐217 inhibits the proliferation, migration, and invasion in non‐small cell lung cancer cells via targeting SIRT1 and P53/KAI1 signaling, Balkan Med J, 37, 208
- 10.1371/journal.pone.0016427 · DOI
- 10.1038/oncsis.2017.12 · DOI
- 10.1080/15384101.2016.1261767 · DOI
- 10.18632/aging.203459 · doi:10.18632/aging.203459
- 10.1080/08830185.2020.1795153 · DOI
- Wu CE, 2022, In vitro and in vivo study of GSK2830371 and RG7388 combination in liver adenocarcinoma, Am J Cancer Res, 12, 4399
- 10.1016/j.ccr.2007.08.033 · DOI · Paper page
- 10.1016/j.tcb.2020.12.011 · DOI · Paper page
- 10.1016/j.ccell.2018.12.012 · DOI · Paper page
- 10.1038/s41568-022-00535-5 · DOI · Paper page
- 10.1002/smll.202205166 · DOI
- 10.3390/cancers15020551 · DOI
- 10.1007/s12282-018-0913-1 · DOI
- 10.1016/j.ando.2019.04.010 · DOI
- 10.1158/0008-5472.CAN-04-3995 · DOI · Paper page
- 10.1023/A:1023725029589 · DOI · Paper page
- 10.1200/JCO.2002.09.147 · DOI
- 10.1200/JCO.1999.17.10.3150 · doi:10.1200/jco.1999.17.10.3150
- 10.3389/fcell.2022.1012179 · doi:10.3389/fcell.2022.1012179
- 10.3390/ijms21030870 · DOI
- 10.3390/ijms21103670 · DOI
- 10.1007/978-1-4614-8289-5_6 · DOI
- 10.1016/j.tig.2019.11.005 · DOI · Paper page
- 10.1111/eos.12685 · DOI
- 10.21873/anticanres.15510 · DOI
- Aljabal G, 2020, 14‐3‐3sigma and its modulators in cancer, Pharmaceuticals (Basel), 13, 10.3390/ph13120441 · DOI
- 10.1111/pin.13147 · DOI
- 10.1158/1078-0432.CCR-03-0510 · DOI
- 10.1016/j.cca.2020.09.009 · DOI
- 10.1128/MCB.23.20.7096-7107.2003 · DOI · Paper page
- 10.1158/2159-8290.CD-22-0244 · DOI
- 10.1002/adma.202207384 · DOI
- 10.1016/j.bbcan.2005.11.002 · DOI · Paper page
- 10.1016/j.cca.2013.05.002 · DOI · Paper page
- 10.1016/j.semcancer.2022.09.006 · DOI
200 of 376 shown
Metadata
- Authors
- Shen, J., Wang, Q., Mao, Y., Gao, W., & Duan, S.
- Venue
- MedComm
- Publisher
- Wiley
- Published
- 2023-05-28
- Volume
- 4
- Issue
- 3
- ISSN
- 2688-2663
- Cited by
- 62
- References
- 44
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting the p53 signaling pathway in cancers: Molecular mechanisms and clinical studies. https://app.cochat.ai/papers/10.1002/mco2.288
- The paper
- Shen, J., Wang, Q., Mao, Y., Gao, W., & Duan, S. (2023). Targeting the p53 signaling pathway in cancers: Molecular mechanisms and clinical studies. MedComm. https://doi.org/10.1002/mco2.288
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.